Otsenka effektivnosti i perenosimosti abiraterona atsetata (Zitiga) u patsientov s metastaticheskim gormonorezistentnym rakom predstatel'noy zhelezy, u kotorykh otmechalas' progressiya opukholevogo protsessa posle khimioterapii taksanami
- Authors: Gafanov RA1, Ivanov SA1, Fastovets SV1, Isaev TK1
-
Affiliations:
- ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ
- Issue: Vol 14, No 2 (2012)
- Pages: 25-28
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29489
- ID: 29489
Cite item
Full Text
Abstract
About the authors
R A Gafanov
ФГБУ Российский научный центр рентгенорадиологии Минздрава РФФГБУ Российский научный центр рентгенорадиологии Минздрава РФ
S A Ivanov
ФГБУ Российский научный центр рентгенорадиологии Минздрава РФФГБУ Российский научный центр рентгенорадиологии Минздрава РФ
S V Fastovets
ФГБУ Российский научный центр рентгенорадиологии Минздрава РФФГБУ Российский научный центр рентгенорадиологии Минздрава РФ
T K Isaev
ФГБУ Российский научный центр рентгенорадиологии Минздрава РФФГБУ Российский научный центр рентгенорадиологии Минздрава РФ
References
- Ferlay J, Shin HR, Bray F et al. GLOBOCAN. Cancer incidence and mortality worldwide: IARC Cancer Base 2008; 10.
- Давыдов М.И., Аксель Е.М. Вестник РОНЦ им. Н.Н.Блохина (Прил. 1). 2011; 22 (3): 13-4.
- Anderson J. Treatment of prostate cancer - the role of primary hormonal therapy. EAU Update (Series 1) 2003; p. 32-9.
- Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
- Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
- Hellerstedt B, Pienta KJ. Prostate cancer and the geriatric patient. In: Principles of geriatric medicine and gerontology (5th ed.).
- Goshman L, Fish J, Roller K. Clinically significant cytochrome P-450 drug interactions. J Pharm Soc Wis 1999; p. 23-38.
- Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-8.
- Stigliano et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007; 194: 55-61.
- Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen independent prostate cancer is associated with increased expression of androgen regulated genes. Cancer Res 1998; 58: 5718-24.
- Labrie F, Cusan L, Gomez JL et al. Long-term combined androgen blockade alone for localized prostate cancer. Molecular Urology 1999; 3: 217-25.
- Ryan C, Smith M, Fong L et al. Phase I clinical trial of CYP17 ingibitor abiraterona acetate demonstrating clinical activity in patient with castration-resistant prostate cancer who received prior ketoconasole therapy. J Clin Oncol 2010; 28: 1481-8.
- Danila D, Morris M, de Bono J et al. Phase II multicenter study of abiraterona acetate plus prednisone therapy in with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501.
- Reid A, Attard G, Danila D et al. Significant and sustained antitumor activate in post docetaxel, castration-resistant prostate cancer with CYP17 ingibitor abiraterona acetate. J Clin Oncol 2010; 286: 1489-95.
- De Bono et al. The New English J Med 2011; 21: 364.
- Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17. Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone. JCO 2008; p. 4563-71.